Regeneron Pharmaceuticals reported third-quarter revenue of $5.1 billion, up 36%, and non-GAAP diluted EPS of $20.07, up 70%. It expects an FDA decision in November for semdiceran in generalized myosthenia gravis.
REGN · Regeneron Pharmaceuticals, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Regeneron Pharmaceuticals, Inc. expanded its Sanofi collaboration in October 2026 to include four additional antibodies, receiving a $1.0 billion up-front payment and up to $7.0 billion in milestones.
Regeneron Pharmaceuticals reported third-quarter 2026 revenues of $5.1 billion, up 36%, and non-GAAP EPS of $20.07, up 70%. Its expanded Sanofi alliance adds $1.0 billion upfront and up to $7.0 billion in future milestones.
Regeneron and Sanofi agreed to co-develop four antibodies, with a $1.0 billion upfront payment and up to $7.0 billion in milestones. Regeneron expects an approximately $22 million pre-tax IPR&D charge and approximately $0.18 diluted-share impact in third quarter 2026.
Regeneron expanded its collaboration with Sanofi to add next-generation type 2 medicines. Regeneron will contribute four long-acting antibodies and receive $1 billion upfront plus up to $7 billion in milestones; the companies will split development costs and global profits 50-50.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Jul 30, 2026TL;DR. Regeneron reported Q2 2026 revenue up 17% to $4.3 billion and non-GAAP EPS up 11% to $14.29, with Dupixent, EYLEA HD, and Libtayo setting all-time-high quarterly net sales. The company fully repaid the Sanofi Development Balance, which will step up collaboration profits starting in Q3, and raised its 2026 non-GAAP gross margin outlook.
- + Total revenue grew 17% to $4.3 billion and non-GAAP EPS grew 11% to $14.29, marking a second consecutive quarter of double-digit top- and bottom-line growth
- + Dupixent global net sales reached an all-time high of $6.0 billion, up 38%, with U.S. sales up 42% to $4.6 billion
- + EYLEA HD U.S. net sales rose 52% to an all-time high of $596 million and now represent ~60% of the U.S. retinal franchise
- + Sanofi Development Balance fully repaid; collaboration profits step up beginning Q3 2026
- + Raised 2026 non-GAAP gross margin on net product sales guidance to 84%-85% (from 83%-84%)
- − EYLEA U.S. net sales fell 45% to $412 million due to conversion to EYLEA HD, competition, and upcoming aflibercept biosimilars
- − Fianlimab Phase 3 in first-line advanced melanoma did not meet statistical significance for the primary PFS endpoint
- − GAAP net income declined 7% to $1,297 million and GAAP diluted EPS fell 5% to $12.23, weighed down by IPR&D charges and lower investment gains
- − GAAP gross margin on net product sales fell to 78% from 83% due to unabsorbed manufacturing costs from the Limerick, Ireland facility interruption
- − Q2 R&D expense rose 15% to $1,632 million and acquired IPR&D charges jumped to $127 million (vs. $10 million prior year), creating a $0.99 per-share non-GAAP drag
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| aggregate payments | $150M | first quarter of 2026 filing | — |
| Capital expenditures | -771M | Nine Months Ended September 30, 2026 | — |
| Company's share of profits from the commercialization of antibodies | 2.58B | Q3 2026 | — |
| Customer A | 48% | the three months ended September 30, 2026 filing | — |
| Customer B | 30% | the three months ended September 30, 2026 filing | — |
| Dupixent global net sales (recorded by Sanofi) | 6.5B | Q3 2026 | — |
|
|
|||
| Evkeeza® - U.S. | 55M | Q3 2026 | — |
| EYLEA | 658.4M | Three Months Ended September 30, 2026 | — |
|
|
|||
| EYLEA HD | 1.08B | Three Months Ended September 30, 2026 | — |
|
|
|||
| EYLEA HD U.S. net sales | 699M | Q3 2026 | — |
| EYLEA U.S. net product sales declined | 41% | the three months ended September 30, 2026 filing | — |
| EYLEA® - U.S. | 400M | Q3 2026 | — |
| Free cash flow non-GAAP | 2.9B | Nine Months Ended September 30, 2026 | — |
| Gross margin on net product sales | 82% | three months ended September 30, 2026 filing | — |
| Kevzara(a) | 255.6M | Three Months Ended September 30, 2026 filing | — |
|
|
|||
| Libtayo - ROW | 154M | Q3 2026 | — |
| Libtayo - U.S. | 396M | Q3 2026 | — |
| Libtayo global net sales | 550M | Q3 2026 | — |
|
|
|||
| Lynozyfic® - Global | 19M | Q3 2026 | — |
|
|
|||
| Other products(e) | 91.3M | Three Months Ended September 30, 2026 filing | — |
| Praluent(d) | 260.9M | Three Months Ended September 30, 2026 filing | — |
| Praluent® - U.S. | 81M | Q3 2026 | — |
| product candidates in clinical development | 50 | Q3 2026 | — |
| reduced liver fat | 70% | 12 weeks | — |
| Regeneron's share of profits as a percentage of Dupixent and Kevzara net product sales | 38% | three months ended September 30, 2026 filing | — |
| Regeneron's share of profits as a percentage of EYLEA 8 mg and EYLEA net product sales outside t | 33% | three months ended September 30, 2026 filing | — |
| Total EYLEA HD and EYLEA | 1.74B | Three Months Ended September 30, 2026 filing | — |
| Total EYLEA HD and EYLEA - U.S. | 1.1B | Q3 2026 | — |
| up-front payment | 1B | October 2026 | — |
| Net product sales of Praluent (Total) | $265.6M | Three Months Ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
REGN
this stock
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
|
ARGX
Argenx SE
|
$60.37B | +14.2% | — | — | 2.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 30, 2026
- This year
- 23
Regeneron Pharmaceuticals, Inc. expanded its Sanofi collaboration in October 2026 to include four additional antibodies, receiving a $1.0 billion up-front payment and up to $7.0 billion in milestones.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| REGN | +5.7% | +20.8% | +50.6% | +3.0% | +23.8% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +3.1% | +22.0% | +50.1% | +3.2% | +13.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.